Chester County News and Community Website
NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced that it will present significant interim findings from its randomized Phase 1b FURTHER study on firmonertinib monotherapy. This presentation …
ArriVent BioPharma to Present Groundbreaking Data at 2024 World Conference on Lung Cancer Read More
HARRISBURG, PA — Secretary of the Commonwealth Al Schmidt announced a dramatic increase in participation for the Cancer Drug Repository Program (CDRP), with the number of pharmacies involved jumping from …
Participation in Pennsylvania’s Cancer Drug Program Soars by 900% Read More
WASHINGTON, D.C. — The Food and Drug Administration (FDA) has announced that the national supply of cisplatin, a key cancer medication, now exceeds demand, ending a critical shortage that began …
FDA Announces End to National Shortage of Crucial Cancer Drug Cisplatin Read More
WASHINGTON, D.C. — The Food and Drug Administration (FDA) recently granted accelerated approval to Epkinly (epcoritamab-bysp), a new treatment option for adults with relapsed or refractory follicular lymphoma (FL). This …
FDA Grants Accelerated Approval to New Treatment for Relapsed Follicular Lymphoma Read More
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) has released new survey results highlighting persistent drug shortages in cancer treatment across the United States. While the availability of …
NCCN Survey Reveals Ongoing Cancer Drug Shortages Despite Improvements Read More
WASHINGTON, D.C. — The Food and Drug Administration (FDA) recently granted accelerated approval for a new treatment combination for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC). …
FDA Grants Accelerated Approval to New Colorectal Cancer Treatment Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) will host a virtual Key Opinion Leader (KOL) event on June 24, 2024, at 9:00 AM ET to discuss APR-1051, their highly …
Aprea Therapeutics Hosts Virtual Event on Promising Cancer Therapy Read More
WASHINGTON, D.C. — On Monday, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) in combination with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary …
FDA Approves Keytruda Combination for Advanced Endometrial Cancer Read More
WASHINGTON, D.C. — On Friday, the Food and Drug Administration (FDA) approved durvalumab (Imfinzi, AstraZeneca UK Limited) for use with carboplatin plus paclitaxel followed by single-agent durvalumab. This approval targets …
FDA Approves New Treatment for Advanced Endometrial Cancer Read More WASHINGTON, D.C. — On Friday, the Food and Drug Administration (FDA) approved blinatumomab (Blincyto, Amgen Inc.) for both adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative …
FDA Approves Blinatumomab for Advanced Leukemia Treatment Read More